3M-052-AF

BIOLOGICAL5 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Valneva Austria GmbH, HIV Vaccine Trials Network

Conditions

HIV InfectionsHIV-1ZikaZika Virus Infection

Phase 1

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

CompletedNCT04177355

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2020-01-13End: 2024-11-04Updated: 2025-09-02

Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV

CompletedNCT05781542

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2023-04-10End: 2025-04-14Updated: 2025-11-14

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

CompletedNCT06334393

Valneva Austria GmbHZika, Zika Virus Infection

Start: 2024-03-25End: 2026-02-27Updated: 2026-03-09

Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected

Not yet recruitingNCT06613789

HIV Vaccine Trials NetworkHIV Infections

Start: 2026-07-13End: 2027-06-03Target: 22Updated: 2025-12-09

Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

SuspendedNCT06680479

National Institute of Allergy and Infectious Diseases (NIAID)HIV-1

Start: 2025-04-01End: 2028-04-14Target: 30Updated: 2026-03-03